Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

COVID-19

Free Subscription Articles published in Antiviral Res Retrieve available abstracts of 214 articles: HTML format

Single Articles

April 2024
1. GLITSCHER M, Benz NI, Sabino C, Murra RO, et al
   Inhibition of Pim kinases triggers a broad antiviral activity by affecting innate immunity and via the PI3K-Akt-mTOR axis the endolysosomal system.
   Antiviral Res. 2024;226:105891.
   PubMed     Abstract available
   
   
   
2. TOLKSDORF B, Heinze J, Niemeyer D, Rohrs V, et al
   Development of a highly stable, active small interfering RNA with broad activity against SARS-CoV viruses.
   Antiviral Res. 2024 Apr 8:105879. doi: 10.1016/j.antiviral.2024.105879.
   PubMed     Abstract available
   
   
   March 2024
3. KHATUA K, Alugubelli YR, Yang KS, Vulupala VR, et al
   Azapeptides with unique covalent warheads as SARS-CoV-2 main protease inhibitors.
   Antiviral Res. 2024;225:105874.
   PubMed     Abstract available
   
   
   
4. SINIAVIN AE, Gushchin VA, Shastina NS, Darnotuk ES, et al
   New conjugates based on N4-hydroxycytidine with more potent antiviral efficacy in vitro than EIDD-2801 against SARS-CoV-2 and other human coronaviruses.
   Antiviral Res. 2024 Mar 28:105871. doi: 10.1016/j.antiviral.2024.105871.
   PubMed     Abstract available
   
   
   
5. PEREZ-VARGAS J, Lemieux G, Thompson CAH, Desilets A, et al
   Nanomolar anti-SARS-CoV-2 Omicron activity of the host-directed TMPRSS2 inhibitor N-0385 and synergistic action with direct-acting antivirals.
   Antiviral Res. 2024 Mar 26:105869. doi: 10.1016/j.antiviral.2024.105869.
   PubMed     Abstract available
   
   
   
6. DE MEYER A, Meuleman P
   Preclinical animal models to evaluate therapeutic antiviral antibodies.
   Antiviral Res. 2024 Mar 26:105843. doi: 10.1016/j.antiviral.2024.105843.
   PubMed     Abstract available
   
   
   
7. MOON C, Porges E, Roberts A, Bacon J, et al
   A combination of nirmatrelvir and ombitasvir boosts inhibition of SARS-CoV-2 replication.
   Antiviral Res. 2024 Mar 14:105859. doi: 10.1016/j.antiviral.2024.105859.
   PubMed     Abstract available
   
   
   
8. BANDYSZEWSKA M, Ambrozek-Latecka M, Hoser G, Grzanka M, et al
   SARS-CoV-2 virus-like particle variants alpha and delta mimic the native viruses in their differential inflammasome activating potential.
   Antiviral Res. 2024 Mar 5:105857. doi: 10.1016/j.antiviral.2024.105857.
   PubMed     Abstract available
   
   
   
9. WANG W, Wang S, Meng X, Zhao Y, et al
   A virus-like particle candidate vaccine based on CRISPR/Cas9 gene editing technology elicits broad-spectrum protection against SARS-CoV-2.
   Antiviral Res. 2024 Mar 4:105854. doi: 10.1016/j.antiviral.2024.105854.
   PubMed     Abstract available
   
   
   
10. KLEVANSKI M, Kim H, Heilemann M, Kuner T, et al
    Glycan-directed SARS-CoV-2 inhibition by leek extract and lectins with insights into the mode-of-action of Concanavalin A.
    Antiviral Res. 2024 Mar 4:105856. doi: 10.1016/j.antiviral.2024.105856.
    PubMed     Abstract available
    
    
    
11. SCHREIBER A, Rodner F, Oberberg N, Anhlan D, et al
    The host-targeted antiviral drug Zapnometinib exhibits a high barrier to the development of SARS-CoV-2 resistance.
    Antiviral Res. 2024 Mar 2:105840. doi: 10.1016/j.antiviral.2024.105840.
    PubMed     Abstract available
    
    
    February 2024
12. NOBORI H, Baba K, Kuroda T, Baba K, et al
    Prophylactic effect of ensitrelvir in mice infected with SARS-CoV-2.
    Antiviral Res. 2024;224:105852.
    PubMed     Abstract available
    
    
    
13. LI H, Sun M, Lei F, Liu J, et al
    Methyl rosmarinate is an allosteric inhibitor of SARS-cov-2 3?C?L protease as a potential candidate against SARS-cov-2 infection.
    Antiviral Res. 2024 Feb 24:105841. doi: 10.1016/j.antiviral.2024.105841.
    PubMed     Abstract available
    
    
    
14. BIGOTTI MG, Klein K, Gan ES, Anastasina M, et al
    The alpha-dystroglycan N-terminus is a broad-spectrum antiviral agent against SARS-CoV-2 and enveloped viruses.
    Antiviral Res. 2024 Feb 20:105837. doi: 10.1016/j.antiviral.2024.105837.
    PubMed     Abstract available
    
    
    
15. SANTOS-FERREIRA N, Van Dycke J, Chiu W, Neyts J, et al
    Molnupiravir inhibits human norovirus and rotavirus replication in 3D human intestinal enteroids.
    Antiviral Res. 2024;223:105839.
    PubMed     Abstract available
    
    
    
16. TAM EH, Peng Y, Yan Cheah MX, Yan C, et al
    Neutralizing antibodies to block viral entry and for identification of entry inhibitors.
    Antiviral Res. 2024 Feb 16:105834. doi: 10.1016/j.antiviral.2024.105834.
    PubMed     Abstract available
    
    
    
17. SINHA D, Yaugel-Novoa M, Waeckel L, Paul S, et al
    Unmasking the potential of secretory IgA and its pivotal role in protection from respiratory viruses.
    Antiviral Res. 2024 Feb 6:105823. doi: 10.1016/j.antiviral.2024.105823.
    PubMed     Abstract available
    
    
    
18. WANG Y, Liu Y, Wang J, Zhang M, et al
    An adenovirus-vectored vaccine based on the N protein of feline coronavirus elicit robust protective immune responses.
    Antiviral Res. 2024;223:105825.
    PubMed     Abstract available
    
    
    
19. JIAO Z, Wang P, Hu X, Chen Y, et al
    Feline infectious peritonitis virus ORF7a is a virulence factor involved in inflammatory pathology in cats.
    Antiviral Res. 2024;222:105794.
    PubMed     Abstract available
    
    
    January 2024
20. WINIGER RR, Perez L
    Therapeutic antibodies and alternative formats against SARS-CoV-2.
    Antiviral Res. 2024 Jan 31:105820. doi: 10.1016/j.antiviral.2024.105820.
    PubMed     Abstract available
    
    
    
21. BOUZIDI HS, Driouich JS, Klitting R, Bernadin O, et al
    Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strains.
    Antiviral Res. 2024 Jan 23:105814. doi: 10.1016/j.antiviral.2024.105814.
    PubMed     Abstract available
    
    
    
22. BOGACHEVA MS, Kuivanen S, Potdar S, Hassinen A, et al
    Drug repurposing platform for deciphering the druggable SARS-CoV-2 interactome.
    Antiviral Res. 2024 Jan 23:105813. doi: 10.1016/j.antiviral.2024.105813.
    PubMed     Abstract available
    
    
    
23. BOND ACS, Crocker MA, Wilczek MP, DuShane JK, et al
    High-throughput drug screen identifies calcium and calmodulin inhibitors that reduce JCPyV infection.
    Antiviral Res. 2024 Jan 19:105817. doi: 10.1016/j.antiviral.2024.105817.
    PubMed     Abstract available
    
    
    
24. IDRIS A, Supramaniam A, Tayyar Y, Kelly G, et al
    An intranasally delivered ultra-conserved siRNA prophylactically represses SARS-CoV-2 infection in the lung and nasal cavity.
    Antiviral Res. 2024;222:105815.
    PubMed     Abstract available
    
    
    
25. GOVEDNIK T, Lainscek D, Kuhar U, Lachish M, et al
    TXM peptides inhibit SARS-CoV-2 infection, syncytia formation, and lower inflammatory consequences.
    Antiviral Res. 2024 Jan 9:105806. doi: 10.1016/j.antiviral.2024.105806.
    PubMed     Abstract available
    
    
    
26. GARCIA-RODRIGUEZ I, Moreni G, Capendale PE, Mulder L, et al
    Assessment of the broad-spectrum host targeting antiviral efficacy of halofuginone hydrobromide in human airway, intestinal and brain organotypic models.
    Antiviral Res. 2024 Jan 6:105798. doi: 10.1016/j.antiviral.2024.105798.
    PubMed     Abstract available
    
    
    December 2023
27. CHEN X, Tian L, Zhang L, Gao W, et al
    Deubiquitinase USP39 promotes SARS-CoV-2 replication by deubiquitinating and stabilizing the envelope protein.
    Antiviral Res. 2023;221:105790.
    PubMed     Abstract available
    
    
    
28. DOIJEN J, Heo I, Temmerman K, Vermeulen P, et al
    A flexible, image-based, high-throughput platform encompassing in-depth cell profiling to identify broad-spectrum coronavirus antivirals with limited off-target effects.
    Antiviral Res. 2023 Dec 27:105789. doi: 10.1016/j.antiviral.2023.105789.
    PubMed     Abstract available
    
    
    
29. AKSU M, Kumar P, Guttler T, Taxer W, et al
    Nanobodies to multiple spike variants and inhalation of nanobody-containing aerosols neutralize SARS-CoV-2 in cell culture and hamsters.
    Antiviral Res. 2023 Dec 6:105778. doi: 10.1016/j.antiviral.2023.105778.
    PubMed     Abstract available
    
    
    
30. WANGEN C, Raithel A, Tillmanns J, Gege C, et al
    Validation of nuclear receptor RORgamma isoform 1 as a novel host-directed antiviral target based on the modulation of cholesterol levels.
    Antiviral Res. 2023 Dec 4:105769. doi: 10.1016/j.antiviral.2023.105769.
    PubMed     Abstract available
    
    
    
31. ZUR M, Peselev T, Yanko S, Rotshild V, et al
    Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: Systematic review and network meta-analysis.
    Antiviral Res. 2023 Dec 4:105768. doi: 10.1016/j.antiviral.2023.105768.
    PubMed     Abstract available
    
    
    
32. WANG S, Wang Z, Li Y, Tu S, et al
    Generation of whole-porcine neutralizing antibodies of an alphacoronavirus by single B cell antibody technology.
    Antiviral Res. 2023;220:105754.
    PubMed     Abstract available
    
    
    November 2023
33. GALLUCCI L, Bazire J, Davidson AD, Shytaj IL, et al
    Broad-spectrum antiviral activity of two structurally analogous CYP3A inhibitors against pathogenic human coronaviruses in vitro.
    Antiviral Res. 2023;221:105766.
    PubMed     Abstract available
    
    
    
34. WANG S, Cui H, Zhang C, Li W, et al
    Oral delivery of a chitosan adjuvanted COVID-19 vaccine provides long-lasting and broad-spectrum protection against SARS-CoV-2 variants of concern in golden hamsters.
    Antiviral Res. 2023 Nov 28:105765. doi: 10.1016/j.antiviral.2023.105765.
    PubMed     Abstract available
    
    
    
35. FORRESTALL K, Pringle ES, Sands D, Duguay BA, et al
    A phenothiazine urea derivative broadly inhibits coronavirus replication via viral protease inhibition.
    Antiviral Res. 2023;220:105758.
    PubMed     Abstract available
    
    
    
36. SUBRAMANI C, Sharma G, Chaira T, Barman TK, et al
    High content screening strategies for large-scale compound libraries with a focus on high-containment viruses.
    Antiviral Res. 2023 Nov 24:105764. doi: 10.1016/j.antiviral.2023.105764.
    PubMed     Abstract available
    
    
    
37. GOMEZ-CARBALLA A, Albericio G, Montoto-Louzao J, Perez P, et al
    Lung transcriptomics of K18-hACE2 mice highlights mechanisms and genes involved in the MVA-S vaccine-mediated immune response and protection against SARS-CoV-2 infection.
    Antiviral Res. 2023 Nov 20:105760. doi: 10.1016/j.antiviral.2023.105760.
    PubMed     Abstract available
    
    
    
38. WU CY, Tseng YC, Kao SE, Wu LY, et al
    Monoglycosylated SARS-CoV-2 receptor binding domain fused with HA(stem)-scaffolded protein vaccine confers broad protective immunity against SARS-CoV-2 and influenza viruses.
    Antiviral Res. 2023 Nov 18:105759. doi: 10.1016/j.antiviral.2023.105759.
    PubMed     Abstract available
    
    
    
39. ZHANG QY, Zhang HQ, Zhang YN, Zhang ZR, et al
    Newcastle Disease Virus (NDV)-based vaccine candidate against SARS-CoV-2 Omicron by intranasal immunization.
    Antiviral Res. 2023 Nov 18:105757. doi: 10.1016/j.antiviral.2023.105757.
    PubMed     Abstract available
    
    
    
40. CHUANG YT, Lin YL, Lin JY
    Licochalcone A regulates viral IRES activity to inhibit enterovirus replication.
    Antiviral Res. 2023 Nov 18:105755. doi: 10.1016/j.antiviral.2023.105755.
    PubMed     Abstract available
    
    
    
41. SADHU S, Dandotiya J, Dalal R, Khatri R, et al
    Fangchinoline inhibits SARS-CoV-2 and MERS-CoV entry.
    Antiviral Res. 2023 Nov 8:105743. doi: 10.1016/j.antiviral.2023.105743.
    PubMed     Abstract available
    
    
    
42. HSIEH HC, Chen CC, Chou PH, Liu WC, et al
    Induction of neutralizing antibodies and mucosal IgA through intranasal immunization with the receptor binding domain of SARS-CoV-2 spike protein fused with the type IIb E. coli heat-labile enterotoxin A subunit.
    Antiviral Res. 2023 Nov 8:105752. doi: 10.1016/j.antiviral.2023.105752.
    PubMed     Abstract available
    
    
    
43. SU WC, Chen ZY, Chang YS, Jeng KS, et al
    Functional assessments of SARS-CoV-2 single-round infectious particles with variant-specific spike proteins on infectivity, drug sensitivity, and antibody neutralization.
    Antiviral Res. 2023 Nov 7:105744. doi: 10.1016/j.antiviral.2023.105744.
    PubMed     Abstract available
    
    
    
44. KIM DG, Kim U, Park IH, Ryu B, et al
    A bivalent form of a RBD-specific synthetic antibody effectively neutralizes SARS-CoV-2 variants.
    Antiviral Res. 2023 Nov 7:105738. doi: 10.1016/j.antiviral.2023.105738.
    PubMed     Abstract available
    
    
    October 2023
45. DEMIAN WL, Jacob RA, Cormier O, Nazli A, et al
    ASK1 inhibitors are potential pan-antiviral drugs, which dampen replication of diverse viruses including SARS-CoV2.
    Antiviral Res. 2023 Oct 18:105736. doi: 10.1016/j.antiviral.2023.105736.
    PubMed     Abstract available
    
    
    
46. PALLA SR, Li CW, Chao TL, Lo HV, et al
    Synthesis, evaluation, and mechanism of 1-(4-(arylethylenylcarbonyl)phenyl)-4-carboxy-2-pyrrolidinones as potent reversible SARS-CoV-2 entry inhibitors.
    Antiviral Res. 2023 Oct 17:105735. doi: 10.1016/j.antiviral.2023.105735.
    PubMed     Abstract available
    
    
    
47. KONKEL R, Milewska A, Do NDT, Barreto Duran E, et al
    Anti-SARS-CoV-2 activity of cyanopeptolins produced by Nostoc edaphicum CCNP1411.
    Antiviral Res. 2023 Oct 12:105731. doi: 10.1016/j.antiviral.2023.105731.
    PubMed     Abstract available
    
    
    
48. MAMATIS JE, Gallardo-Flores CE, Sangwan U, Tooley TH, et al
    Induction of antiviral gene expression by cyclosporine a, but not inhibition of cyclophilin a or B, contributes to its restriction of human coronavirus 229E infection in a lung epithelial cell line.
    Antiviral Res. 2023 Oct 5:105730. doi: 10.1016/j.antiviral.2023.105730.
    PubMed     Abstract available
    
    
    September 2023
49. BENNETT RP, Yoluc Y, Salter JD, Ripp A, et al
    Corrigendum to ' Sangivamycin is preferentially incorporated into viral RNA by the SARS-CoV-2 polymerase' [Antiviral Research 218 (2023) 105716-105728/ doi: 10.1016/j.antiviral.2023.105716].
    Antiviral Res. 2023 Sep 28:105729. doi: 10.1016/j.antiviral.2023.105729.
    PubMed    
    
    
    
50. MCMILLAN RE, Lo MK, Zhang XQ, Beadle JR, et al
    Enhanced broad spectrum in vitro antiviral efficacy of 3-F-4-MeO-Bn, 3-CN, and 4-CN derivatives of lipid remdesivir nucleoside monophosphate prodrugs.
    Antiviral Res. 2023 Sep 25:105718. doi: 10.1016/j.antiviral.2023.105718.
    PubMed     Abstract available
    
    
    
51. BENNETT RP, Yoluc Y, Salter JD, Ripp A, et al
    Sangivamycin is preferentially incorporated into viral RNA by the SARS-CoV-2 polymerase.
    Antiviral Res. 2023 Sep 8:105716. doi: 10.1016/j.antiviral.2023.105716.
    PubMed     Abstract available
    
    
    
52. MARTIN HJ, Melo-Filho CC, Korn D, Eastman RT, et al
    Small molecule antiviral compound collection (SMACC): A comprehensive, highly curated database to support the discovery of broad-spectrum antiviral drug molecules.
    Antiviral Res. 2023;217:105620.
    PubMed     Abstract available
    
    
    August 2023
53. VANDERLINDEN E, Boonen A, Noppen S, Schoofs G, et al
    PRO-2000 exhibits SARS-CoV-2 antiviral activity by interfering with spike-heparin binding.
    Antiviral Res. 2023;217:105700.
    PubMed     Abstract available
    
    
    
54. CORONA A, Madia VN, De Santis R, Manelfi C, et al
    Diketo acid inhibitors of nsp13 of SARS-CoV-2 block viral replication.
    Antiviral Res. 2023;217:105697.
    PubMed     Abstract available
    
    
    July 2023
55. SPENGLER JR, Carter K, Delang L, Durantel D, et al
    Meeting report: 36th international conference on antiviral research in Lyon, France, March 13-17, 2023.
    Antiviral Res. 2023 Jul 24:105678. doi: 10.1016/j.antiviral.2023.105678.
    PubMed     Abstract available
    
    
    
56. SUPREWICZ L, Szczepanski A, Lenart M, Piktel E, et al
    Ceragenins exhibit antiviral activity against SARS-CoV-2 by increasing the expression and release of type I interferons upon activation of the host's immune response.
    Antiviral Res. 2023 Jul 20:105676. doi: 10.1016/j.antiviral.2023.105676.
    PubMed     Abstract available
    
    
    
57. BOWDEN-REID E, Ledger S, Zhang Y, Di Giallonardo F, et al
    Novel siRNA therapeutics demonstrate multi-variant efficacy against SARS-CoV-2.
    Antiviral Res. 2023 Jul 19:105677. doi: 10.1016/j.antiviral.2023.105677.
    PubMed     Abstract available
    
    
    
58. LI Y, Wang Y, Li Y, de Vries AC, et al
    Seasonal coronavirus infections trigger NLRP3 inflammasome activation in macrophages but is therapeutically targetable.
    Antiviral Res. 2023 Jul 15:105674. doi: 10.1016/j.antiviral.2023.105674.
    PubMed     Abstract available
    
    
    
59. TAKASHITA E, Fujisaki S, Morita H, Nagata S, et al
    Assessment of the frequency of SARS-CoV-2 Omicron variant escape from RNA-dependent RNA polymerase inhibitors and 3C-like protease inhibitors.
    Antiviral Res. 2023;216:105671.
    PubMed     Abstract available
    
    
    
60. JEONG JH, Choi JH, Kim BK, Min SC, et al
    Evaluating Z-FA-FMK, a host cathepsin L protease inhibitor, as a potent and broad-spectrum antiviral therapy against SARS-CoV-2 and related coronaviruses.
    Antiviral Res. 2023 Jul 10:105669. doi: 10.1016/j.antiviral.2023.105669.
    PubMed     Abstract available
    
    
    
61. FENG Y, Yang Y, Zou S, Qiu S, et al
    Identification of alpha-linolenic acid as a broad-spectrum antiviral against zika, dengue, herpes simplex, influenza virus and SARS-CoV-2 infection.
    Antiviral Res. 2023 Jul 8:105666. doi: 10.1016/j.antiviral.2023.105666.
    PubMed     Abstract available
    
    
    June 2023
62. CAI H, Yan J, Liu S, Li P, et al
    Paxlovid for hospitalized COVID-19 patients with chronic kidney disease.
    Antiviral Res. 2023 Jun 25:105659. doi: 10.1016/j.antiviral.2023.105659.
    PubMed     Abstract available
    
    
    
63. MILAN BONOTTO R, Mitrovic A, Sosic I, Martinez-Orellana P, et al
    Cathepsin inhibitors nitroxoline and its derivatives inhibit SARS-CoV-2 infection.
    Antiviral Res. 2023;216:105655.
    PubMed     Abstract available
    
    
    
64. JUNG HE, Ku KB, Kang BH, Park JH, et al
    Intranasal delivery of an adenovirus-vector vaccine co-expressing a modified spike protein and a genetic adjuvant confers lasting mucosal immunity against SARS-CoV-2.
    Antiviral Res. 2023;216:105656.
    PubMed     Abstract available
    
    
    
65. CHANG YJ, Le UNP, Liu JJ, Li SR, et al
    Combining virtual screening with cis-/trans-cleavage enzymatic assays effectively reveals broad-spectrum inhibitors that target the main proteases of SARS-CoV-2 and MERS-CoV.
    Antiviral Res. 2023 Jun 13:105653. doi: 10.1016/j.antiviral.2023.105653.
    PubMed     Abstract available
    
    
    May 2023
66. DRIOUICH JS, Bernadin O, Touret F, de Lamballerie X, et al
    Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster model.
    Antiviral Res. 2023 May 17:105638. doi: 10.1016/j.antiviral.2023.105638.
    PubMed     Abstract available
    
    
    
67. HUANG X, Fan W, Sun J, Yang J, et al
    SARS-CoV-2 induces cardiomyocyte apoptosis and inflammation but can be ameliorated by ACE inhibitor Captopril.
    Antiviral Res. 2023 May 17:105636. doi: 10.1016/j.antiviral.2023.105636.
    PubMed     Abstract available
    
    
    April 2023
68. CHO J, Shin Y, Yang JS, Kim JW, et al
    Evaluation of antiviral drugs against newly emerged SARS-CoV-2 Omicron subvariants.
    Antiviral Res. 2023;214:105609.
    PubMed     Abstract available
    
    
    
69. LI Y, Wang K, Sun H, Wu S, et al
    Omicsynin B4 potently blocks coronavirus infection by inhibiting host proteases cathepsin L and TMPRSS2.
    Antiviral Res. 2023 Apr 17:105606. doi: 10.1016/j.antiviral.2023.105606.
    PubMed     Abstract available
    
    
    
70. CONG Y, Lee JH, Perry DL, Cooper K, et al
    Longitudinal analyses using (18)F-Fluorodeoxyglucose positron emission tomography with computed tomography as a measure of COVID-19 severity in the aged, young, and humanized ACE2 SARS-CoV-2 hamster models.
    Antiviral Res. 2023 Apr 15:105605. doi: 10.1016/j.antiviral.2023.105605.
    PubMed     Abstract available
    
    
    March 2023
71. BILLS C, Xie X, Shi PY
    The multiple roles of nsp6 in the molecular pathogenesis of SARS-CoV-2.
    Antiviral Res. 2023;213:105590.
    PubMed     Abstract available
    
    
    
72. CONG Y, Mucker EM, Perry DL, Dixit S, et al
    Evaluation of a panel of therapeutic antibody clinical candidates for efficacy against SARS-CoV-2 in Syrian hamsters.
    Antiviral Res. 2023;213:105589.
    PubMed     Abstract available
    
    
    
73. PEREZ-VARGAS J, Shapira T, Olmstead AD, Villanueva I, et al
    Corrigendum to "Discovery of lead natural products for developing pan-SARS-CoV-2 therapeutics" "Antiviral Research 209 (2023)/105484".
    Antiviral Res. 2023 Mar 30:105577. doi: 10.1016/j.antiviral.2023.105577.
    PubMed    
    
    
    
74. YANG Y, Cao L, Yan M, Zhou J, et al
    Synthesis of deuterated S-217622 (Ensitrelvir) with antiviral activity against coronaviruses including SARS-CoV-2.
    Antiviral Res. 2023 Mar 28:105586. doi: 10.1016/j.antiviral.2023.105586.
    PubMed     Abstract available
    
    
    
75. VANHULLE E, Doijen J, Stroobants J, Provinciael B, et al
    Cellular electrical impedance to profile SARS-CoV-2 fusion inhibitors and to assess the fusogenic potential of spike mutants.
    Antiviral Res. 2023;213:105587.
    PubMed     Abstract available
    
    
    
76. DICHTL S, Diem G, Jager M, Zaderer V, et al
    Antiviral drugs block replication of highly immune-evasive Omicron subvariants ex vivo, but fail to reduce tissue inflammation.
    Antiviral Res. 2023 Mar 23:105581. doi: 10.1016/j.antiviral.2023.105581.
    PubMed     Abstract available
    
    
    
77. ALVES RPDS, Wang YT, Mikulski Z, McArdle S, et al
    SARS-CoV-2 Omicron (B.1.1.529) shows minimal neurotropism in a double-humanized mouse model.
    Antiviral Res. 2023 Mar 18:105580. doi: 10.1016/j.antiviral.2023.105580.
    PubMed     Abstract available
    
    
    
78. LIANG JQ, Xie MY, Hou L, Wang HL, et al
    miRNAs derived from milk small extracellular vesicles inhibit porcine epidemic diarrhea virus infection.
    Antiviral Res. 2023 Mar 10:105579. doi: 10.1016/j.antiviral.2023.105579.
    PubMed     Abstract available
    
    
    
79. LU C, Zhang Y, Liu X, Hou F, et al
    Heterologous boost with mRNA vaccines against SARS-CoV-2 Delta/Omicron variants following an inactivated whole-virus vaccine.
    Antiviral Res. 2023;212:105556.
    PubMed     Abstract available
    
    
    
80. KIM JW, Heo K, Kim HJ, Yoo Y, et al
    Novel bispecific human antibody platform specifically targeting a fully open spike conformation potently neutralizes multiple SARS-CoV-2 variants.
    Antiviral Res. 2023;212:105576.
    PubMed     Abstract available
    
    
    
81. SHEKUNOV EV, Zlodeeva PD, Efimova SS, Muryleva AA, et al
    Cyclic lipopeptides as membrane fusion inhibitors against SARS-CoV-2: New tricks for old dogs.
    Antiviral Res. 2023;212:105575.
    PubMed     Abstract available
    
    
    
82. HU Y, Zhu Y, Yu Y, Liu N, et al
    Design and characterization of novel SARS-CoV-2 fusion inhibitors with N-terminally extended HR2 peptides.
    Antiviral Res. 2023;212:105571.
    PubMed     Abstract available
    
    
    February 2023
83. ZHAO L, Yao L, Chen R, He J, et al
    Pinosrtobin from plants and propolis against human coronavirus HCoV-OC43 by modulating host AHR/CYP1A1 pathway and lipid metabolism.
    Antiviral Res. 2023 Feb 28:105570. doi: 10.1016/j.antiviral.2023.105570.
    PubMed     Abstract available
    
    
    
84. XIAO Y, Yan Y, Chang L, Ji H, et al
    CDK4/6 inhibitor palbociclib promotes SARS-CoV-2 cell entry by down-regulating SKP2 dependent ACE2 degradation.
    Antiviral Res. 2023 Feb 18:105558. doi: 10.1016/j.antiviral.2023.105558.
    PubMed     Abstract available
    
    
    
85. LI J, Wang Y, Solanki K, Atre R, et al
    Nirmatrelvir exerts distinct antiviral potency against different human coronaviruses.
    Antiviral Res. 2023 Feb 13:105555. doi: 10.1016/j.antiviral.2023.105555.
    PubMed     Abstract available
    
    
    
86. MERINO VF, Yan Y, Ordonez AA, Bullen CK, et al
    Nucleolin mediates SARS-CoV-2 replication and viral-induced apoptosis of host cells.
    Antiviral Res. 2023;211:105550.
    PubMed     Abstract available
    
    
    
87. KURHADE C, Xie X, Shi PY
    Reverse genetic systems of SARS-CoV-2 for antiviral research.
    Antiviral Res. 2023;210:105486.
    PubMed     Abstract available
    
    
    January 2023
88. ZHU Y, Li M, Liu N, Wu T, et al
    Development of highly effective LCB1-based lipopeptides targeting the spike receptor-binding motif of SARS-CoV-2.
    Antiviral Res. 2023;211:105541.
    PubMed     Abstract available
    
    
    
89. BASILE A, Zannella C, De Marco M, Sanna G, et al
    Spike-mediated viral membrane fusion is inhibited by a specific anti-IFITM2 monoclonal antibody.
    Antiviral Res. 2023;211:105546.
    PubMed     Abstract available
    
    
    December 2022
90. SPENGLER JR, Welch SR, Deval J, Gentry BG, et al
    Meeting report: 35th international conference on antiviral research in Seattle, WA, USA - March 21-25, 2022.
    Antiviral Res. 2022 Dec 31:105521. doi: 10.1016/j.antiviral.2022.105521.
    PubMed     Abstract available
    
    
    
91. CHISTOV AA, Chumakov SP, Mikhnovets IE, Nikitin TD, et al
    5-(Perylen-3-ylethynyl)uracil as an antiviral scaffold: Potent suppression of enveloped virus reproduction by 3-methyl derivatives in vitro.
    Antiviral Res. 2022 Dec 26:105508. doi: 10.1016/j.antiviral.2022.105508.
    PubMed     Abstract available
    
    
    
92. LIM SP
    Targeting SARS-CoV-2 and host cell receptor interactions.
    Antiviral Res. 2022 Dec 26:105514. doi: 10.1016/j.antiviral.2022.105514.
    PubMed     Abstract available
    
    
    
93. HU L, Tang Y, Mei L, Liang M, et al
    A new intracellular targeting motif in the cytoplasmic tail of the spike protein may act as a target to inhibit SARS-CoV-2 assembly.
    Antiviral Res. 2022;209:105509.
    PubMed     Abstract available
    
    
    
94. TNG DJH, Low JGH
    Current status of silica-based nanoparticles as therapeutics and its potential as therapies against viruses.
    Antiviral Res. 2022 Dec 22:105488. doi: 10.1016/j.antiviral.2022.105488.
    PubMed     Abstract available
    
    
    
95. SHANNON A, Canard B
    Kill or corrupt: Mechanisms of action and drug-resistance of nucleotide analogues against SARS-CoV-2.
    Antiviral Res. 2022 Dec 21:105501. doi: 10.1016/j.antiviral.2022.105501.
    PubMed     Abstract available
    
    
    
96. CHIU W, Schepers J, Francken T, Vangeel L, et al
    Development of a robust and convenient dual-reporter high-throughput screening assay for SARS-CoV-2 antiviral drug discovery.
    Antiviral Res. 2022 Dec 21:105506. doi: 10.1016/j.antiviral.2022.105506.
    PubMed     Abstract available
    
    
    
97. ZHANG YN, Zhang HQ, Wang GF, Zhang ZR, et al
    Intranasal delivery of replicating mRNA encoding hACE2-targeting antibody against SARS-CoV-2 Omicron infection in the hamster.
    Antiviral Res. 2022;209:105507.
    PubMed     Abstract available
    
    
    
98. JOHNSON DM, Brasel T, Massey S, Garron T, et al
    Evaluation of molnupiravir (EIDD-2801) efficacy against SARS-CoV-2 in the rhesus macaque model.
    Antiviral Res. 2022 Dec 16:105492. doi: 10.1016/j.antiviral.2022.105492.
    PubMed     Abstract available
    
    
    
99. PEREZ-VARGAS J, Shapira T, Olmstead AD, Villanueva I, et al
    Discovery of lead natural products for developing pan-SARS-CoV-2 therapeutics.
    Antiviral Res. 2022 Dec 8:105484. doi: 10.1016/j.antiviral.2022.105484.
    PubMed     Abstract available
    
    
    
100. HASHIZUME M, Takashima A, Ono C, Okamoto T, et al
     Phenothiazines inhibit SARS-CoV-2 cell entry via a blockade of spike protein binding to neuropilin-1.
     Antiviral Res. 2022 Dec 5:105481. doi: 10.1016/j.antiviral.2022.105481.
     PubMed     Abstract available
     
     
     
101. YAO Y, Sun H, Chen Y, Tian L, et al
     RBM24 inhibits the translation of SARS-CoV-2 polyproteins by targeting the 5'-untranslated region.
     Antiviral Res. 2022;209:105478.
     PubMed     Abstract available
     
     
     November 2022
102. JEONG K, Chang J, Park SM, Kim J, et al
     Rapid discovery and classification of inhibitors of coronavirus infection by pseudovirus screen and amplified luminescence proximity homogeneous assay.
     Antiviral Res. 2022 Nov 23:105473. doi: 10.1016/j.antiviral.2022.105473.
     PubMed     Abstract available
     
     
     
103. FAIST A, Schloer S, Mecate-Zambrano A, Janowski J, et al
     Inhibition of p38 signaling curtails the SARS-CoV-2 induced inflammatory response but retains the IFN-dependent antiviral defense of the lung epithelial barrier.
     Antiviral Res. 2022 Nov 21:105475. doi: 10.1016/j.antiviral.2022.105475.
     PubMed     Abstract available
     
     
     
104. HUI X, Yu X, Huang K, Xu T, et al
     In vitro and in vivo effects of 3-indoleacetonitrile-A potential new broad-spectrum therapeutic agent for SARS-CoV-2 infection.
     Antiviral Res. 2022 Nov 16:105465. doi: 10.1016/j.antiviral.2022.105465.
     PubMed     Abstract available
     
     
     
105. FABREGA-FERRER M, Herrera-Morande A, Muriel-Goni S, Perez-Saavedra J, et al
     Structure and inhibition of SARS-CoV-1 and SARS-CoV-2 main proteases by oral antiviral compound AG7404.
     Antiviral Res. 2022;208:105458.
     PubMed     Abstract available
     
     
     
106. ZENG Y, Song F, Luo G, Yang H, et al
     Generation and characterization of mouse monoclonal antibodies against the VP4 protein of group A human rotaviruses.
     Antiviral Res. 2022;207:105407.
     PubMed     Abstract available
     
     
     October 2022
107. ZHANG T, Su S, Altouma V, Zhu X, et al
     Topoisomerase 3b is dispensable for replication of a positive-sense RNA virus--murine coronavirus.
     Antiviral Res. 2022 Oct 31:105451. doi: 10.1016/j.antiviral.2022.105451.
     PubMed     Abstract available
     
     
     
108. VARRICCHIO C, Mathez G, Pillonel T, Bertelli C, et al
     Geneticin shows selective antiviral activity against SARS-CoV-2 by interfering with programmed -1 ribosomal frameshifting.
     Antiviral Res. 2022;208:105452.
     PubMed     Abstract available
     
     
     
109. SHANG W, Dai W, Yao C, Xu L, et al
     In vitro and in vivo evaluation of the main protease inhibitor FB2001 against SARS-CoV-2.
     Antiviral Res. 2022;208:105450.
     PubMed     Abstract available
     
     
     
110. ZHU Y, Hu Y, Liu N, Chong H, et al
     Potent inhibition of diverse Omicron sublineages by SARS-CoV-2 fusion-inhibitory lipopeptides.
     Antiviral Res. 2022;208:105445.
     PubMed     Abstract available
     
     
     
111. KIM TY, Kim JY, Kwon HC, Jeon S, et al
     Astersaponin I from Aster koraiensis is a natural viral fusion blocker that inhibit the infection of SARS-CoV-2 variants and syncytium formation.
     Antiviral Res. 2022 Oct 14:105428. doi: 10.1016/j.antiviral.2022.105428.
     PubMed     Abstract available
     
     
     
112. BRAY M
     Antiviral Research: At age 41, a transition.
     Antiviral Res. 2022 Oct 14:105447. doi: 10.1016/j.antiviral.2022.105447.
     PubMed     Abstract available
     
     
     
113. JEONG JH, Chokkakula S, Min SC, Kim BK, et al
     Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected mice.
     Antiviral Res. 2022;208:105430.
     PubMed     Abstract available
     
     
     
114. ZHU Y, Binder J, Yurgelonis I, Rai D, et al
     Generation of a VeroE6 Pgp gene knock out cell line and its use in SARS-CoV-2 antiviral study.
     Antiviral Res. 2022 Oct 5:105429. doi: 10.1016/j.antiviral.2022.105429.
     PubMed     Abstract available
     
     
     September 2022
115. MA L, Li Q, Xie Y, Jianyuan Zhao, et al
     Repurposing of HIV/HCV protease inhibitors against SARS-CoV-2 3CL(pro).
     Antiviral Res. 2022 Sep 22:105419. doi: 10.1016/j.antiviral.2022.105419.
     PubMed     Abstract available
     
     
     August 2022
116. DEMAREST JF, Kienle M, Boytz R, Ayres M, et al
     Brequinar and dipyridamole in combination exhibits synergistic antiviral activity against SARS-CoV-2 in vitro: Rationale for a host-acting antiviral treatment strategy for COVID-19.
     Antiviral Res. 2022 Aug 27:105403. doi: 10.1016/j.antiviral.2022.105403.
     PubMed     Abstract available
     
     
     
117. LAI M, De Carli A, Filipponi C, Iacono E, et al
     Lipid balance remodelling by human positive-strand RNA viruses and the contribution of lysosomes.
     Antiviral Res. 2022 Aug 17:105398. doi: 10.1016/j.antiviral.2022.105398.
     PubMed     Abstract available
     
     
     
118. LU L, Peng Y, Yao H, Wang Y, et al
     Punicalagin as an allosteric NSP13 helicase inhibitor potently suppresses SARS-CoV-2 replication in vitro.
     Antiviral Res. 2022 Aug 16:105389. doi: 10.1016/j.antiviral.2022.105389.
     PubMed     Abstract available
     
     
     July 2022
119. LI M, Chen J, Liu Y, Zhao J, et al
     Rational design of AAVrh10-vectored ACE2 functional domain to broadly block the cell entry of SARS-CoV-2 variants.
     Antiviral Res. 2022 Jul 30:105383. doi: 10.1016/j.antiviral.2022.105383.
     PubMed     Abstract available
     
     
     
120. SAMRAT SK, Xu J, Xie X, Gianti E, et al
     Allosteric inhibitors of the main protease of SARS-CoV-2.
     Antiviral Res. 2022;205:105381.
     PubMed     Abstract available
     
     
     
121. BEZERRA BB, Silva GPDD, Antunes Coelho SV, Correa IA, et al
     Hydroxypropyl-beta-cyclodextrin (HP-BCD) inhibits SARS-CoV-2 replication and virus-induced inflammatory cytokines.
     Antiviral Res. 2022 Jul 4:105373. doi: 10.1016/j.antiviral.2022.105373.
     PubMed     Abstract available
     
     
     
122. OHASHI H, Hishiki T, Akazawa D, Kim KS, et al
     Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2.
     Antiviral Res. 2022 Jul 4:105372. doi: 10.1016/j.antiviral.2022.105372.
     PubMed     Abstract available
     
     
     June 2022
123. KIM EH, Lee BW, Ryu B, Cho HM, et al
     Inhibition of a broad range of SARS-CoV-2 variants by antiviral phytochemicals in hACE2 mice.
     Antiviral Res. 2022;204:105371.
     PubMed     Abstract available
     
     
     
124. SEEPHETDEE C, Bhukhai K, Buasri N, Leelukkanaveera P, et al
     A circular mRNA vaccine prototype producing VFLIP-X spike confers a broad neutralization of SARS-CoV-2 variants by mouse sera.
     Antiviral Res. 2022 Jun 27:105370. doi: 10.1016/j.antiviral.2022.105370.
     PubMed     Abstract available
     
     
     
125. KARIM M, Saul S, Ghita L, Sahoo MK, et al
     Numb-associated kinases are required for SARS-CoV-2 infection and are cellular targets for antiviral strategies.
     Antiviral Res. 2022 Jun 20:105367. doi: 10.1016/j.antiviral.2022.105367.
     PubMed     Abstract available
     
     
     
126. ZHOU M, Liu Y, Cao J, Dong S, et al
     Bergamottin, a bioactive component of bergamot, inhibits SARS-CoV-2 infection in golden Syrian hamsters.
     Antiviral Res. 2022 Jun 19:105365. doi: 10.1016/j.antiviral.2022.105365.
     PubMed     Abstract available
     
     
     
127. HERNANDEZ S, Feracci M, De Jesus CT, El Kazzi P, et al
     Identification of potent inhibitors of arenavirus and SARS-CoV-2 exoribonucleases by fluorescence polarization assay.
     Antiviral Res. 2022 Jun 15:105364. doi: 10.1016/j.antiviral.2022.105364.
     PubMed     Abstract available
     
     
     
128. MELO-FILHO CC, Bobrowski T, Martin HJ, Sessions Z, et al
     Conserved coronavirus proteins as targets of broad-spectrum antivirals.
     Antiviral Res. 2022 Jun 9:105360. doi: 10.1016/j.antiviral.2022.105360.
     PubMed     Abstract available
     
     
     
129. MERCORELLI B, Desantis J, Celegato M, Bazzacco A, et al
     Discovery of novel SARS-CoV-2 inhibitors targeting the main protease M(pro) by virtual screenings and hit optimization.
     Antiviral Res. 2022;204:105350.
     PubMed     Abstract available
     
     
     May 2022
130. PRASHAR P, Swain S, Adhikari N, Aryan P, et al
     A novel high-throughput single B-cell cloning platform for isolation and characterization of high-affinity and potent SARS-CoV-2 neutralizing antibodies.
     Antiviral Res. 2022 May 28:105349. doi: 10.1016/j.antiviral.2022.105349.
     PubMed     Abstract available
     
     
     
131. LIN Q, Lu C, Hong Y, Li R, et al
     Animal models for studying coronavirus infections and developing antiviral agents and vaccines.
     Antiviral Res. 2022 May 20:105345. doi: 10.1016/j.antiviral.2022.105345.
     PubMed     Abstract available
     
     
     
132. ROY A, Alhammad YM, McDonald P, Johnson DK, et al
     Discovery of compounds that inhibit SARS-CoV-2 Mac1-ADP-ribose binding by high-throughput screening.
     Antiviral Res. 2022 May 19:105344. doi: 10.1016/j.antiviral.2022.105344.
     PubMed     Abstract available
     
     
     
133. WEIL T, Lawrenz J, Seidel A, Munch J, et al
     Immunodetection assays for the quantification of seasonal common cold coronaviruses OC43, NL63, or 229E infection confirm nirmatrelvir as broad coronavirus inhibitor.
     Antiviral Res. 2022 May 19:105343. doi: 10.1016/j.antiviral.2022.105343.
     PubMed     Abstract available
     
     
     
134. VANHULLE E, Stroobants J, Provinciael B, Camps A, et al
     SARS-CoV-2 Permissive glioblastoma cell line for high throughput antiviral screening.
     Antiviral Res. 2022 May 17:105342. doi: 10.1016/j.antiviral.2022.105342.
     PubMed     Abstract available
     
     
     
135. FINDLAY-WILSON S, Easterbrook L, Smith S, Pope N, et al
     Development of a cost-effective ovine antibody-based therapy against SARS-CoV-2 infection and contribution of antibodies specific to the spike subunit proteins.
     Antiviral Res. 2022 May 6:105332. doi: 10.1016/j.antiviral.2022.105332.
     PubMed     Abstract available
     
     
     
136. PITTS J, Babusis D, Vermillion MS, Subramanian R, et al
     Intravenous delivery of GS-441524 is efficacious in the African green monkey model of SARS-CoV-2 infection.
     Antiviral Res. 2022 May 4:105329. doi: 10.1016/j.antiviral.2022.105329.
     PubMed     Abstract available
     
     
     April 2022
137. FOO CS, Abdelnabi R, Kaptein SJF, Zhang X, et al
     HIV protease inhibitors Nelfinavir and Lopinavir/Ritonavir markedly improve lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect.
     Antiviral Res. 2022;202:105311.
     PubMed     Abstract available
     
     
     
138. VANMECHELEN B, Stroobants J, Chiu W, Schepers J, et al
     Identification of novel Ebola virus inhibitors using biologically contained virus.
     Antiviral Res. 2022;200:105294.
     PubMed     Abstract available
     
     
     March 2022
139. UENO M, Iwata-Yoshikawa N, Matsunaga A, Okamura T, et al
     Isolation of human monoclonal antibodies with neutralizing activity to a broad spectrum of SARS-CoV-2 viruses including the Omicron variants.
     Antiviral Res. 2022;201:105297.
     PubMed     Abstract available
     
     
     
140. LAI GC, Chao TL, Lin SY, Kao HC, et al
     Neutralization or enhancement of SARS-CoV-2 infection by a monoclonal antibody targeting a specific epitope in the spike receptor-binding domain.
     Antiviral Res. 2022;200:105290.
     PubMed     Abstract available
     
     
     
141. PASQUERO S, Gugliesi F, Griffante G, Dell'Oste V, et al
     Novel antiviral activity of PAD inhibitors against human beta-coronaviruses HCoV-OC43 and SARS-CoV-2.
     Antiviral Res. 2022;200:105278.
     PubMed     Abstract available
     
     
     
142. CHEN KY, Krischuns T, Varga LO, Harigua-Souiai E, et al
     A highly sensitive cell-based luciferase assay for high-throughput automated screening of SARS-CoV-2 nsp5/3CLpro inhibitors.
     Antiviral Res. 2022 Mar 9:105272. doi: 10.1016/j.antiviral.2022.105272.
     PubMed     Abstract available
     
     
     
143. SCHOLLE MD, O'Kane PT, Dib S, Gurard-Levin ZA, et al
     Label-free duplex SAMDI-MS screen reveals novel SARS-CoV-2 3CLpro inhibitors.
     Antiviral Res. 2022;200:105279.
     PubMed     Abstract available
     
     
     
144. TANAKA T, Saito A, Suzuki T, Miyamoto Y, et al
     Establishment of a stable SARS-CoV-2 replicon system for application in high-throughput screening.
     Antiviral Res. 2022;199:105268.
     PubMed     Abstract available
     
     
     February 2022
145. TSAI TI, Khalili JS, Gilchrist M, Waight AB, et al
     ACE2-Fc fusion protein overcomes viral escape by potently neutralizing SARS-CoV-2 variants of concern.
     Antiviral Res. 2022 Feb 28:105271. doi: 10.1016/j.antiviral.2022.105271.
     PubMed     Abstract available
     
     
     
146. SACHSE M, Tenorio R, Fernandez de Castro I, Munoz-Basagoiti J, et al
     Unraveling the antiviral activity of plitidepsin by subcellular and morphological analysis.
     Antiviral Res. 2022 Feb 26:105270. doi: 10.1016/j.antiviral.2022.105270.
     PubMed     Abstract available
     
     
     January 2022
147. ZHAO J, Liu Q, Yi D, Li Q, et al
     5-Iodotubercidin inhibits SARS-CoV-2 RNA synthesis.
     Antiviral Res. 2022 Jan 28:105254. doi: 10.1016/j.antiviral.2022.105254.
     PubMed     Abstract available
     
     
     
148. VANGEEL L, Chiu W, De Jonghe S, Maes P, et al
     Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern.
     Antiviral Res. 2022 Jan 24:105252. doi: 10.1016/j.antiviral.2022.105252.
     PubMed     Abstract available
     
     
     
149. ABDELNABI R, Foo CS, Zhang X, Lemmens V, et al
     The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters.
     Antiviral Res. 2022 Jan 20:105253. doi: 10.1016/j.antiviral.2022.105253.
     PubMed     Abstract available
     
     
     
150. FOCOSI D, Maggi F, McConnell S, Casadevall A, et al
     Very low levels of remdesivir resistance in SARS-COV-2 genomes after 18 months of massive usage during the COVID19 pandemic: A GISAID exploratory analysis.
     Antiviral Res. 2022;198:105247.
     PubMed     Abstract available
     
     
     
151. WILLIAMSON BN, Perez-Perez L, Schwarz B, Feldmann F, et al
     Subcutaneous remdesivir administration prevents interstitial pneumonia in rhesus macaques inoculated with SARS-CoV-2.
     Antiviral Res. 2022 Jan 12:105246. doi: 10.1016/j.antiviral.2022.105246.
     PubMed     Abstract available
     
     
     December 2021
152. KUMAR R, Khandelwal N, Chander Y, Nagori H, et al
     S-adenosylmethionine-dependent methyltransferase inhibitor DZNep blocks transcription and translation of SARS-CoV-2 genome with a low tendency to select for drug-resistant viral variants.
     Antiviral Res. 2021 Dec 27:105232. doi: 10.1016/j.antiviral.2021.105232.
     PubMed     Abstract available
     
     
     
153. MCKIMM-BRESCHKIN JL, Hay AJ, Cao B, Cox RJ, et al
     COVID-19, Influenza and RSV: Surveillance-informed prevention and treatment - Meeting report from an isirv-WHO virtual conference.
     Antiviral Res. 2021 Dec 18:105227. doi: 10.1016/j.antiviral.2021.105227.
     PubMed     Abstract available
     
     
     November 2021
154. COCHIN M, Touret F, Driouich JS, Moureau G, et al
     Hydroxychloroquine and azithromycin used alone or combined are not effective against SARS-CoV-2 ex vivo and in a hamster model.
     Antiviral Res. 2021;197:105212.
     PubMed     Abstract available
     
     
     
155. ZHAO J, Zhang G, Zhang Y, Yi D, et al
     2-((1H-indol-3-yl)thio)-N-phenyl-acetamides: SARS-CoV-2 RNA-dependent RNA polymerase inhibitors.
     Antiviral Res. 2021;196:105209.
     PubMed     Abstract available
     
     
     
156. SVILENOV HL, Sacherl J, Reiter A, Wolff LS, et al
     Picomolar inhibition of SARS-CoV-2 variants of concern by an engineered ACE2-IgG4-Fc fusion protein.
     Antiviral Res. 2021 Nov 10:105197. doi: 10.1016/j.antiviral.2021.105197.
     PubMed     Abstract available
     
     
     
157. QIU H, Yuan XY, Cabral T, Manguiat K, et al
     Development and characterization of SARS-CoV-2 variant-neutralizing monoclonal antibodies.
     Antiviral Res. 2021 Nov 8:105206. doi: 10.1016/j.antiviral.2021.105206.
     PubMed     Abstract available
     
     
     October 2021
158. WANG YT, Allen RD 3rd, Kim K, Shafee N, et al
     SARS-CoV-2 monoclonal antibodies with therapeutic potential: Broad neutralizing activity and No evidence of antibody-dependent enhancement.
     Antiviral Res. 2021 Oct 8:105185. doi: 10.1016/j.antiviral.2021.105185.
     PubMed     Abstract available
     
     
     
159. DEY-RAO R, Smith GR, Timilsina U, Falls Z, et al
     A fluorescence-based, gain-of-signal, live cell system to evaluate SARS-CoV-2 main protease inhibition.
     Antiviral Res. 2021;195:105183.
     PubMed     Abstract available
     
     
     September 2021
160. JULANDER JG, Demarest JF, Taylor R, Gowen BB, et al
     An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviral.
     Antiviral Res. 2021 Sep 19:105180. doi: 10.1016/j.antiviral.2021.105180.
     PubMed     Abstract available
     
     
     August 2021
161. GARCIA-DORIVAL I, Cuesta-Geijo MA, Barrado-Gil L, Galindo I, et al
     Identification of Niemann-Pick C1 protein as a potential novel SARS-CoV-2 intracellular target.
     Antiviral Res. 2021 Aug 24:105167. doi: 10.1016/j.antiviral.2021.105167.
     PubMed     Abstract available
     
     
     
162. ESCAFFRE O, Freiberg AN
     Polyphenylene carboxymethylene (PPCM) microbicide repurposed as antiviral against SARS-CoV-2. Proof of concept in primary human undifferentiated epithelial cells.
     Antiviral Res. 2021 Aug 9:105162. doi: 10.1016/j.antiviral.2021.105162.
     PubMed     Abstract available
     
     
     
163. LEACH A, Ilca FT, Akbar Z, Ferrari M, et al
     A tetrameric ACE2 protein broadly neutralizes SARS-CoV-2 spike variants of concern with elevated potency.
     Antiviral Res. 2021 Aug 7:105147. doi: 10.1016/j.antiviral.2021.105147.
     PubMed     Abstract available
     
     
     
164. ISON MG, Hayden FG, Hay AJ, Gubareva LV, et al
     Influenza polymerase inhibitor resistance: Assessment of the current state of the art - A report of the isirv Antiviral group.
     Antiviral Res. 2021;194:105158.
     PubMed     Abstract available
     
     
     July 2021
165. KASPRZYK R, Spiewla TJ, Smietanski M, Golojuch S, et al
     Identification and evaluation of potential SARS-CoV-2 antiviral agents targeting mRNA cap guanine N7-Methyltransferase.
     Antiviral Res. 2021;193:105142.
     PubMed     Abstract available
     
     
     
166. TOURET F, Driouich JS, Cochin M, Petit PR, et al
     Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2.
     Antiviral Res. 2021;193:105137.
     PubMed     Abstract available
     
     
     
167. GAN ES, Syenina A, Linster M, Ng B, et al
     A mouse model of lethal respiratory dysfunction for SARS-CoV-2 infection.
     Antiviral Res. 2021;193:105138.
     PubMed     Abstract available
     
     
     
168. PERSOONS L, Vanderlinden E, Vangeel L, Wang X, et al
     Broad spectrum anti-coronavirus activity of a series of anti-malaria quinoline analogues.
     Antiviral Res. 2021 Jul 1:105127. doi: 10.1016/j.antiviral.2021.105127.
     PubMed     Abstract available
     
     
     June 2021
169. DO TND, Donckers K, Vangeel L, Chatterjee AK, et al
     A robust SARS-CoV-2 replication model in primary human epithelial cells at the air liquid interface to assess antiviral agents.
     Antiviral Res. 2021 Jun 26:105122. doi: 10.1016/j.antiviral.2021.105122.
     PubMed     Abstract available
     
     
     
170. KASHYAP T, Murray J, Walker CJ, Chang H, et al
     Selinexor, a novel selective inhibitor of nuclear export, reduces SARS-CoV-2 infection and protects the respiratory system in vivo.
     Antiviral Res. 2021 Jun 19:105115. doi: 10.1016/j.antiviral.2021.105115.
     PubMed     Abstract available
     
     
     May 2021
171. PAULL JRA, Heery GP, Bobardt MD, Castellarnau A, et al
     Virucidal and antiviral activity of astodrimer sodium against SARS-CoV-2 in vitro.
     Antiviral Res. 2021 May 16:105089. doi: 10.1016/j.antiviral.2021.105089.
     PubMed     Abstract available
     
     
     April 2021
172. ZHAO J, Guo S, Yi D, Li Q, et al
     A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase.
     Antiviral Res. 2021;190:105078.
     PubMed     Abstract available
     
     
     
173. DU R, Cooper L, Chen Z, Lee H, et al
     Discovery of Chebulagic Acid and Punicalagin as Novel Allosteric Inhibitors of SARS-CoV-2 3CL(pro).
     Antiviral Res. 2021 Apr 16:105075. doi: 10.1016/j.antiviral.2021.105075.
     PubMed     Abstract available
     
     
     March 2021
174. CICCOSANTI F, Di Rienzo M, Romagnoli A, Colavita F, et al
     Proteomic Analysis Identifies the RNA Helicase DDX3X as a Host Target Against SARS-CoV-2 Infection.
     Antiviral Res. 2021 Mar 26:105064. doi: 10.1016/j.antiviral.2021.105064.
     PubMed     Abstract available
     
     
     
175. MILANI M, Donalisio M, Bonotto RM, Schneider E, et al
     Combined in silico and in vitro approaches identified the antipsychotic drug lurasidone and the antiviral drug elbasvir as SARS-CoV2 and HCoV-OC43 inhibitors.
     Antiviral Res. 2021 Mar 10:105055. doi: 10.1016/j.antiviral.2021.105055.
     PubMed     Abstract available
     
     
     
176. KUMAR R, Afsar M, Khandelwal N, Chander Y, et al
     Emetine suppresses SARS-CoV-2 replication by inhibiting interaction of viral mRNA with eIF4E.
     Antiviral Res. 2021 Mar 9:105056. doi: 10.1016/j.antiviral.2021.105056.
     PubMed     Abstract available
     
     
     February 2021
177. MARTIN R, Li J, Parvangada A, Perry J, et al
     Genetic Conservation of SARS-CoV-2 RNA Replication Complex in Globally Circulating Isolates and Recently Emerged Variants from Humans and Minks Suggests Minimal Pre-Existing Resistance to Remdesivir.
     Antiviral Res. 2021 Feb 4:105033. doi: 10.1016/j.antiviral.2021.105033.
     PubMed     Abstract available
     
     
     January 2021
178. LIU C, Boland S, Scholle MD, Bardiot D, et al
     Dual Inhibition of SARS-CoV-2 and Human Rhinovirus with Protease Inhibitors in Clinical Development.
     Antiviral Res. 2021 Jan 27:105020. doi: 10.1016/j.antiviral.2021.105020.
     PubMed     Abstract available
     
     
     
179. ZHU Q, Zhang Y, Wang L, Yao X, et al
     Inhibition of coronavirus infection by a synthetic STING agonist in primary human airway system.
     Antiviral Res. 2021 Jan 11:105015. doi: 10.1016/j.antiviral.2021.105015.
     PubMed     Abstract available
     
     
     
180. MULLER C, Obermann W, Karl N, Wendel HG, et al
     The rocaglate CR-31-B (-) inhibits SARS-CoV-2 replication at non-cytotoxic, low nanomolar concentrations in vitro and ex vivo.
     Antiviral Res. 2021;186:105012.
     PubMed     Abstract available
     
     
     December 2020
181. SUN X, Li L, Pan L, Wang Z, et al
     Infectious bronchitis virus: Identification of Gallus gallus APN high-affinity ligands with antiviral effects.
     Antiviral Res. 2020 Dec 16:104998. doi: 10.1016/j.antiviral.2020.104998.
     PubMed     Abstract available
     
     
     
182. GAN HJ, Harikishore A, Lee J, Jeon S, et al
     Antiviral activity against Middle East Respiratory Syndrome coronavirus by Montelukast, an anti-asthma drug.
     Antiviral Res. 2020;185:104996.
     PubMed     Abstract available
     
     
     November 2020
183. GALINDO I, Garaigorta U, Lasala F, Cuesta-Geijo MA, et al
     Antiviral drugs targeting endosomal membrane proteins inhibit distant animal and human pathogenic viruses.
     Antiviral Res. 2020 Nov 26:104990. doi: 10.1016/j.antiviral.2020.104990.
     PubMed     Abstract available
     
     
     
184. SVENNINGSEN EB, Thyrsted J, Blay-Cadanet J, Liu H, et al
     Ionophore antibiotic X-206 is a potent inhibitor of SARS-CoV-2 infection in vitro.
     Antiviral Res. 2020 Nov 25:104988. doi: 10.1016/j.antiviral.2020.104988.
     PubMed     Abstract available
     
     
     
185. ZHANG Y, Song W, Chen S, Yuan Z, et al
     A bacterial artificial chromosome (BAC)-vectored noninfectious replicon of SARS-CoV-2.
     Antiviral Res. 2020 Nov 17:104974. doi: 10.1016/j.antiviral.2020.104974.
     PubMed     Abstract available
     
     
     October 2020
186. CHOI SW, Shin JS, Park SJ, Jung E, et al
     Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes.
     Antiviral Res. 2020 Oct 19:104955. doi: 10.1016/j.antiviral.2020.104955.
     PubMed     Abstract available
     
     
     September 2020
187. THEERAWATANASIRIKUL S, Kuo CJ, Phecharat N, Chootip J, et al
     Structural-based virtual screening and in vitro assays for small molecules inhibiting the feline coronavirus 3CL protease as a surrogate platform for coronaviruses.
     Antiviral Res. 2020 Sep 7:104927. doi: 10.1016/j.antiviral.2020.104927.
     PubMed     Abstract available
     
     
     
188. GURARD-LEVIN ZA, Liu C, Jekle A, Jaisinghani R, et al
     Evaluation of SARS-CoV-2 3C-like protease inhibitors using self-assembled monolayer desorption ionization mass spectrometry.
     Antiviral Res. 2020 Sep 4:104924. doi: 10.1016/j.antiviral.2020.104924.
     PubMed     Abstract available
     
     
     August 2020
189. KONKOLOVA E, Dejmek M, Hrebabecky H, Sala M, et al
     Remdesivir triphosphate can efficiently inhibit the RNA-dependent RNA polymerase from various flaviviruses.
     Antiviral Res. 2020 Aug 4:104899. doi: 10.1016/j.antiviral.2020.104899.
     PubMed     Abstract available
     
     
     
190. JEON YJ, Gil CH, Jo A, Won J, et al
     The influence of interferon-lambda on restricting Middle East Respiratory Syndrome Coronavirus replication in the respiratory epithelium.
     Antiviral Res. 2020;180:104860.
     PubMed     Abstract available
     
     
     July 2020
191. OKAMOTO M, Toyama M, Baba M
     The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro.
     Antiviral Res. 2020 Jul 30:104902. doi: 10.1016/j.antiviral.2020.104902.
     PubMed     Abstract available
     
     
     
192. CONZELMANN C, Gilg A, Gross R, Schutz D, et al
     An enzyme-based immunodetection assay to quantify SARS-CoV-2 infection.
     Antiviral Res. 2020 Jul 29:104882. doi: 10.1016/j.antiviral.2020.104882.
     PubMed     Abstract available
     
     
     
193. PRASANTH KR, Hirano M, Fagg WS, McAnarney ET, et al
     Topoisomerase III-ss is required for efficient replication of positive-sense RNA viruses.
     Antiviral Res. 2020 Jul 28:104874. doi: 10.1016/j.antiviral.2020.104874.
     PubMed     Abstract available
     
     
     
194. GALLIAN P, Pastorino B, Morel P, Chiaroni J, et al
     Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors.
     Antiviral Res. 2020 Jul 14:104880. doi: 10.1016/j.antiviral.2020.104880.
     PubMed     Abstract available
     
     
     
195. PIZZORNO A, Padey B, Dubois J, Julien T, et al
     In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2.
     Antiviral Res. 2020 Jul 14:104878. doi: 10.1016/j.antiviral.2020.104878.
     PubMed     Abstract available
     
     
     
196. VENISSE N, Peytavin G, Bouchet S, Gagnieu MC, et al
     Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection.
     Antiviral Res. 2020 Jul 10:104866. doi: 10.1016/j.antiviral.2020.104866.
     PubMed     Abstract available
     
     
     
197. PAN X, Zhou P, Fan T, Wu Y, et al
     Immunoglobulin fragment F(ab')2 against RBD potently neutralizes SARS-CoV-2 in vitro.
     Antiviral Res. 2020 Jul 10:104868. doi: 10.1016/j.antiviral.2020.104868.
     PubMed     Abstract available
     
     
     
198. KIM SY, Jin W, Sood A, Montgomery DW, et al
     Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions.
     Antiviral Res. 2020 Jul 9:104873. doi: 10.1016/j.antiviral.2020.104873.
     PubMed     Abstract available
     
     
     June 2020
199. JOCKUSCH S, Tao C, Li X, Anderson TK, et al
     A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19.
     Antiviral Res. 2020;180:104857.
     PubMed     Abstract available
     
     
     
200. SHANNON A, Le NT, Selisko B, Eydoux C, et al
     Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites.
     Antiviral Res. 2020;178:104793.
     PubMed     Abstract available
     
     
     May 2020
201. TAI W, Zhang X, He Y, Jiang S, et al
     Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2.
     Antiviral Res. 2020 May 13:104820. doi: 10.1016/j.antiviral.2020.104820.
     PubMed     Abstract available
     
     
     April 2020
202. MANTLO E, Bukreyeva N, Maruyama J, Paessler S, et al
     Antiviral activities of type I interferons to SARS-CoV-2 infection.
     Antiviral Res. 2020;179:104811.
     PubMed     Abstract available
     
     
     
203. BRAY M, Rayner C, Noel F, Jans D, et al
     Ivermectin and COVID-19: a report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses.
     Antiviral Res. 2020 Apr 21:104805. doi: 10.1016/j.antiviral.2020.104805.
     PubMed    
     
     
     
204. SALLARD E, Lescure FX, Yazdanpanah Y, Mentre F, et al
     Type 1 interferons as a potential treatment against COVID-19.
     Antiviral Res. 2020;178:104791.
     PubMed     Abstract available
     
     
     
205. TANG T, Bidon M, Jaimes JA, Whittaker GR, et al
     Coronavirus membrane fusion mechanism offers as a potential target for antiviral development.
     Antiviral Res. 2020 Apr 6:104792. doi: 10.1016/j.antiviral.2020.104792.
     PubMed     Abstract available
     
     
     
206. CALY L, Druce JD, Catton MG, Jans DA, et al
     The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro.
     Antiviral Res. 2020 Apr 3:104787. doi: 10.1016/j.antiviral.2020.104787.
     PubMed     Abstract available
     
     
     
207. CHOY KT, Yin-Lam Wong A, Kaewpreedee P, Sia SF, et al
     Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro.
     Antiviral Res. 2020 Apr 3:104786. doi: 10.1016/j.antiviral.2020.104786.
     PubMed     Abstract available
     
     
     March 2020
208. TOURET F, de Lamballerie X
     Of chloroquine and COVID-19.
     Antiviral Res. 2020;177:104762.
     PubMed     Abstract available
     
     
     
209. SIGRIST C, Bridge A, Le Mercier P
     A potential role for integrins in host cell entry by SARS-CoV-2.
     Antiviral Res. 2020 Mar 1:104759. doi: 10.1016/j.antiviral.2020.104759.
     PubMed    
     
     
     February 2020
210. COUTARD B, Valle C, de Lamballerie X, Canard B, et al
     The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade.
     Antiviral Res. 2020;176:104742.
     PubMed     Abstract available
     
     
     
211. CLASMAN JR, Everett RK, Srinivasan K, Mesecar AD, et al
     Decoupling deISGylating and deubiquitinating activities of the MERS virus papain-like protease.
     Antiviral Res. 2020;174:104661.
     PubMed     Abstract available
     
     
     January 2020
212. NIU J, Shen L, Huang B, Ye F, et al
     Non-invasive bioluminescence imaging of HCoV-OC43 infection and therapy in the central nervous system of live mice.
     Antiviral Res. 2020;173:104646.
     PubMed     Abstract available
     
     
     
213. MA-LAUER Y, Zheng Y, Malesevic M, von Brunn B, et al
     Influences of cyclosporin A and non-immunosuppressive derivatives on cellular cyclophilins and viral nucleocapsid protein during human coronavirus 229E replication.
     Antiviral Res. 2020;173:104620.
     PubMed     Abstract available
     
     
     December 2019
214. THEERAWATANASIRIKUL S, Kuo CJ, Phetcharat N, Lekcharoensuk P, et al
     In silico and in vitro analysis of small molecules and natural compounds targeting the 3CL protease of feline infectious peritonitis virus.
     Antiviral Res. 2019;174:104697.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO COVID-19 is free of charge.